Monroig Kaitlin, Ghosh Kanad, Marquez Jocellie E, Medrano Christopher, Marmor William A, McAuliffe Phoebe, Ferrier Austin, Kapadia Kailash, Rogoff Hunter, Huston Tara, Ganz Jason, Khan Sami, Dagum Alexander, Bui Duc
From the Division of Plastic and Reconstructive Surgery, Department of Surgery, Stony Brook University Hospital.
Division of Plastic and Reconstructive Surgery, Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ.
Ann Plast Surg. 2020 Jul;85(S1 Suppl 1):S50-S53. doi: 10.1097/SAP.0000000000002325.
Many surgeons are reluctant to discontinue prophylactic antibiotics after 24 hours in tissue expander breast reconstruction (TEBR) because of fear of increased risk of surgical site infection (SSI). Currently, there is no consensus regarding antibiotic prophylaxis duration in TEBR. In addition, there remains a lack of research investigating microorganisms involved in SSI across various perioperative antibiotic protocols. The purpose of this study was to examine how 2 different prophylactic antibiotic regimens impacted the bacterial profiles of SSI and rate of implant loss after TEBR.
A single-institution retrospective review of immediate TEBRs between 2001 and 2018 was performed. Surgical site infections requiring hospitalization before stage 2 were included. Highly virulent organisms were defined as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species). Implant loss was defined as removal of tissue expander without immediate replacement.
Of 660 TEBRs, 85 (12.9%) developed an SSI requiring hospitalization before stage 2. Fifty-six (65.9%) received less than 24 hours of perioperative intravenous antibiotics and oral antibiotics after discharge (group 1), and 29 (34.1%) received less than 24 hours of intravenous antibiotics only (group 2). There was no significant difference in demographics, preoperative chemotherapy/radiation, acellular dermal matrix usage, or treatment of SSI between groups. In group 1, 64% (n = 36) developed culture positive SSIs, compared with 83% (n = 24) in group 2 (P = 0.076). Staphylococcus aureus was the most common bacteria in both groups. Group 2 demonstrated a significantly increased incidence of gram-positive organisms (46.4% vs 72.4%, P = 0.022) and S. aureus (21.4% vs 55.2%, P = 0.002). However, there was no significant difference in overall highly virulent (P = 0.168), gram-negative (P = 0.416), or total isolated organisms (P = 0.192). Implant loss between groups 1 and 2 (62.5% vs 62.1%, P = 0.969) respectively, was nearly identical.
Our study demonstrates that, despite differences in bacterial profiles between 2 antibiotic protocols, prolonged postoperative antibiotic use did not protect against overall highly virulent infections or implant loss. Antibiotic stewardship guidelines against the overuse of prolonged prophylactic regimens should be considered. Further analysis regarding timing of SSIs and antibiotic treatment is warranted.
在组织扩张器乳房重建术(TEBR)中,许多外科医生因担心手术部位感染(SSI)风险增加而不愿在24小时后停用预防性抗生素。目前,关于TEBR中抗生素预防持续时间尚无共识。此外,对于不同围手术期抗生素方案下涉及SSI的微生物的研究仍然不足。本研究的目的是探讨两种不同的预防性抗生素方案如何影响TEBR后SSI的细菌谱和植入物丢失率。
对2001年至2018年间进行的即刻TEBR进行单机构回顾性研究。纳入在二期手术前需要住院治疗的手术部位感染。高毒力微生物被定义为ESKAPE病原体(粪肠球菌、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌、铜绿假单胞菌、肠杆菌属)。植入物丢失定义为组织扩张器移除且未立即更换。
在660例TEBR中,85例(12.9%)发生了在二期手术前需要住院治疗的SSI。56例(65.9%)患者围手术期接受静脉抗生素治疗少于24小时且出院后接受口服抗生素治疗(第1组),29例(34.1%)患者仅接受静脉抗生素治疗少于24小时(第2组)。两组在人口统计学、术前化疗/放疗、无细胞真皮基质使用情况或SSI治疗方面无显著差异。在第1组中,64%(n = 36)发生培养阳性的SSI,而第2组为83%(n = 24)(P = 0.076)。金黄色葡萄球菌是两组中最常见的细菌。第2组革兰氏阳性菌(46.4%对72.4%,P = 0.022)和金黄色葡萄球菌(21.4%对55.2%,P = 0.002)的发生率显著增加。然而,在总体高毒力菌(P = 0.168)、革兰氏阴性菌(P = 0.416)或总分离菌(P = 0.192)方面无显著差异。第1组和第组2的植入物丢失率分别为62.5%和62.1%(P = 0.969),几乎相同。
我们的研究表明,尽管两种抗生素方案的细菌谱不同,但术后延长抗生素使用并不能预防总体高毒力感染或植入物丢失。应考虑针对长期预防性方案过度使用的抗生素管理指南。有必要对SSI的发生时间和抗生素治疗进行进一步分析。